Tetomilast.

Authors
O'Mahony, Seamus
Affiliation
Cork University Hospital, Wilton, Cork, Ireland. omahonys3@shb.ie
Issue Date
2012-02-03T15:07:08Z
MeSH
3',5'-Cyclic-AMP Phosphodiesterases/*drug effects
Animals
Anti-Inflammatory Agents, Non-Steroidal/adverse effects/chemical
synthesis/contraindications/pharmacology/*therapeutic use
Clinical Trials as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Colitis, Ulcerative/drug therapy
Cyclic Nucleotide Phosphodiesterases, Type 4
Humans
Phosphodiesterase Inhibitors/adverse effects/chemical
synthesis/contraindications/pharmacology/*therapeutic use
Pulmonary Disease, Chronic Obstructive/drug therapy
Structure-Activity Relationship
Thiazoles/adverse effects/chemical
synthesis/contraindications/pharmacology/*therapeutic use

Metadata
Show full item record
Citation
IDrugs. 2005 Jun;8(6):502-7.
Journal
IDrugs : the investigational drugs journal
URI
http://hdl.handle.net/10147/208909
PubMed ID
15906198
Abstract
Otsuka is developing a once-daily oral formulation of the phosphodiesterase-4 inhibitor tetomilast for the potential treatment of ulcerative colitis (phase III) and chronic obstructive pulmonary disease (phase II).
Language
eng
ISSN
1369-7056 (Print)
1369-7056 (Linking)
Collections